1
|
Bodin S, Previti S, Jestin E, Vimont D, Ait-Arsa I, Lamare F, Rémond E, Hindié E, Cavelier F, Morgat C. Design, Synthesis, and Biological Evaluation of the First Radio-Metalated Neurotensin Analogue Targeting Neurotensin Receptor 2. ACS OMEGA 2023; 8:6994-7004. [PMID: 36844603 PMCID: PMC9948202 DOI: 10.1021/acsomega.2c07814] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 01/30/2023] [Indexed: 05/28/2023]
Abstract
Neurotensin receptor 2 (NTS2) is a well-known mediator of central opioid-independent analgesia. Seminal studies have highlighted NTS2 overexpression in a variety of tumors including prostate cancer, pancreas adenocarcinoma, and breast cancer. Herein, we describe the first radiometalated neurotensin analogue targeting NTS2. JMV 7488 (DOTA-(βAla)2-Lys-Lys-Pro-(D)Trp-Ile-TMSAla-OH) was prepared using solid-phase peptide synthesis, then purified, radiolabeled with 68Ga and 111In, and investigated in vitro on HT-29 cells and MCF-7 cells, respectively, and in vivo on HT-29 xenografts. [68Ga]Ga-JMV 7488 and [111In]In-JMV 7488 were quite hydrophilic (logD7.4 = -3.1 ± 0.2 and -2.7 ± 0.2, respectively, p < 0.0001). Saturation binding studies showed good affinity toward NTS2 (K D = 38 ± 17 nM for [68Ga]Ga-JMV 7488 on HT-29 and 36 ± 10 nM on MCF-7 cells; K D = 36 ± 4 nM for [111In]In-JMV 7488 on HT-29 and 46 ± 1 nM on MCF-7 cells) and good selectivity (no NTS1 binding up to 500 nM). On cell-based evaluation, [68Ga]Ga-JMV 7488 and [111In]In-JMV 7488 showed high and fast NTS2-mediated internalization of 24 ± 5 and 25 ± 11% at 1 h for [111In]In-JMV 7488, respectively, along with low NTS2-membrane binding (<8%). Efflux was as high as 66 ± 9% at 45 min for [68Ga]Ga-JMV 7488 on HT-29 and increased for [111In]In-JMV 7488 up to 73 ± 16% on HT-29 and 78 ± 9% on MCF-7 cells at 2 h. Maximum intracellular calcium mobilization of JMV 7488 was 91 ± 11% to that of levocabastine, a known NTS2 agonist on HT-29 cells demonstrating the agonist behavior of JMV 7488. In nude mice bearing HT-29 xenograft, [68Ga]Ga-JMV 7488 showed a moderate but promising significant tumor uptake in biodistribution studies that competes well with other nonmetalated radiotracers targeting NTS2. Significant uptake was also depicted in lungs. Interestingly, mice prostate also demonstrated [68Ga]Ga-JMV 7488 uptake although the mechanism was not NTS2-mediated.
Collapse
Affiliation(s)
- Sacha Bodin
- Department
of Nuclear Medicine, University Hospital
of Bordeaux, 33076 Bordeaux, France
- University
of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
| | - Santo Previti
- Institut
des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université
de Montpellier, ENSCM, 1919 route de Mende, 34293 Montpellier cedex 5, France
| | - Emmanuelle Jestin
- Cyclotron
Réunion Océan Indien CYROI, 2 rue Maxime Rivière, 97490 Sainte Clotilde, France
| | - Delphine Vimont
- University
of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
| | - Imade Ait-Arsa
- Cyclotron
Réunion Océan Indien CYROI, 2 rue Maxime Rivière, 97490 Sainte Clotilde, France
| | - Frédéric Lamare
- Department
of Nuclear Medicine, University Hospital
of Bordeaux, 33076 Bordeaux, France
- University
of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
| | - Emmanuelle Rémond
- Institut
des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université
de Montpellier, ENSCM, 1919 route de Mende, 34293 Montpellier cedex 5, France
| | - Elif Hindié
- Department
of Nuclear Medicine, University Hospital
of Bordeaux, 33076 Bordeaux, France
- University
of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Institut
Universitaire de France, 1 rue Descartes, 75231 Paris, France
| | - Florine Cavelier
- Institut
des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université
de Montpellier, ENSCM, 1919 route de Mende, 34293 Montpellier cedex 5, France
| | - Clément Morgat
- Department
of Nuclear Medicine, University Hospital
of Bordeaux, 33076 Bordeaux, France
- University
of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
| |
Collapse
|
2
|
Previti S, Desgagné M, Tourwé D, Cavelier F, Sarret P, Ballet S. Opening the amino acid toolbox for peptide-based NTS2-selective ligands as promising lead compounds for pain management. J Pept Sci 2022; 29:e3471. [PMID: 36539999 DOI: 10.1002/psc.3471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Revised: 12/17/2022] [Accepted: 12/19/2022] [Indexed: 12/24/2022]
Abstract
Chronic pain is one of the most critical health issues worldwide. Despite considerable efforts to find therapeutic alternatives, opioid drugs remain the gold standard for pain management. The administration of μ-opioid receptor (MOR) agonists is associated with detrimental and limiting adverse effects. Overall, these adverse effects strongly overshadow the effectiveness of opioid therapy. In this context, the development of neurotensin (NT) ligands has shown to be a promising approach for the management of chronic and acute pain. NT exerts its opioid-independent analgesic effects through the binding of two G protein-coupled receptors (GPCRs), NTS1 and NTS2. In the last decades, modified NT analogues have been proven to provide potent analgesia in vivo. However, selective NTS1 and nonselective NTS1/NTS2 ligands cause antinociception associated with hypothermia and hypotension, whereas selective NTS2 ligands induce analgesia without altering the body temperature and blood pressure. In light of this, various structure-activity relationship (SAR) studies provided findings addressing the binding affinity of ligands towards NTS2. Herein, we comprehensively review peptide-based NTS2-selective ligands as a robust alternative for future pain management. Particular emphasis is placed on SAR studies governing the desired selectivity and associated in vivo results.
Collapse
Affiliation(s)
- Santo Previti
- Research Group of Organic Chemistry, Vrije Universiteit Brussel, Brussels, Belgium.,Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy
| | - Michael Desgagné
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada
| | - Dirk Tourwé
- Research Group of Organic Chemistry, Vrije Universiteit Brussel, Brussels, Belgium
| | - Florine Cavelier
- Institut des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France
| | - Philippe Sarret
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada
| | - Steven Ballet
- Research Group of Organic Chemistry, Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|
3
|
Vivancos M, Fanelli R, Besserer-Offroy É, Beaulieu S, Chartier M, Resua-Rojas M, Mona CE, Previti S, Rémond E, Longpré JM, Cavelier F, Sarret P. Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia. Behav Brain Res 2021; 405:113189. [PMID: 33607165 DOI: 10.1016/j.bbr.2021.113189] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 02/10/2021] [Accepted: 02/11/2021] [Indexed: 12/14/2022]
Abstract
The endogenous tridecapeptide neurotensin (NT) has emerged as an important inhibitory modulator of pain transmission, exerting its analgesic action through the activation of the G protein-coupled receptors, NTS1 and NTS2. Whereas both NT receptors mediate the analgesic effects of NT, NTS1 activation also produces hypotension and hypothermia, which may represent obstacles for the development of new pain medications. In the present study, we implemented various chemical strategies to improve the metabolic stability of the biologically active fragment NT(8-13) and assessed their NTS1/NTS2 relative binding affinities. We then determined their ability to reduce the nociceptive behaviors in acute, tonic, and chronic pain models and to modulate blood pressure and body temperature. To this end, we synthesized a series of NT(8-13) analogs carrying a reduced amide bond at Lys8-Lys9 and harboring site-selective modifications with unnatural amino acids, such as silaproline (Sip) and trimethylsilylalanine (TMSAla). Incorporation of Sip and TMSAla respectively in positions 10 and 13 of NT(8-13) combined with the Lys8-Lys9 reduced amine bond (JMV5296) greatly prolonged the plasma half-life time over 20 h. These modifications also led to a 25-fold peptide selectivity toward NTS2. More importantly, central delivery of JMV5296 was able to induce a strong antinociceptive effect in acute (tail-flick), tonic (formalin), and chronic inflammatory (CFA) pain models without inducing hypothermia. Altogether, these results demonstrate that the chemically-modified NT(8-13) analog JMV5296 exhibits a better therapeutic profile and may thus represent a promising avenue to guide the development of new stable NT agonists and improve pain management.
Collapse
Affiliation(s)
- Mélanie Vivancos
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
| | - Roberto Fanelli
- Institut des Biomolécules Max Mousseron (IBMM), UMR-CNRS 5247, Université Montpellier, ENSCM, Montpellier, France.
| | - Élie Besserer-Offroy
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
| | - Sabrina Beaulieu
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
| | - Magali Chartier
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Martin Resua-Rojas
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
| | - Christine E Mona
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA, USA.
| | - Santo Previti
- Institut des Biomolécules Max Mousseron (IBMM), UMR-CNRS 5247, Université Montpellier, ENSCM, Montpellier, France.
| | - Emmanuelle Rémond
- Institut des Biomolécules Max Mousseron (IBMM), UMR-CNRS 5247, Université Montpellier, ENSCM, Montpellier, France.
| | - Jean-Michel Longpré
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
| | - Florine Cavelier
- Institut des Biomolécules Max Mousseron (IBMM), UMR-CNRS 5247, Université Montpellier, ENSCM, Montpellier, France.
| | - Philippe Sarret
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
| |
Collapse
|
4
|
Gonzalez S, Dumitrascuta M, Eiselt E, Louis S, Kunze L, Blasiol A, Vivancos M, Previti S, Dewolf E, Martin C, Tourwé D, Cavelier F, Gendron L, Sarret P, Spetea M, Ballet S. Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies. J Med Chem 2020; 63:12929-12941. [PMID: 32902268 PMCID: PMC7667639 DOI: 10.1021/acs.jmedchem.0c01376] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Indexed: 01/20/2023]
Abstract
Fusion of nonopioid pharmacophores, such as neurotensin, with opioid ligands represents an attractive approach for pain treatment. Herein, the μ-/δ-opioid agonist tetrapeptide H-Dmt-d-Arg-Aba-β-Ala-NH2 (KGOP01) was fused to NT(8-13) analogues. Since the NTS1 receptor has been linked to adverse effects, selective MOR-NTS2 ligands are preferred. Modifications were introduced within the native NT sequence, particularly a β3-homo amino acid in position 8 and Tyr11 substitutions. Combination of β3hArg and Dmt led to peptide 7, a MOR agonist, showing the highest NTS2 affinity described to date (Ki = 3 pM) and good NTS1 affinity (Ki = 4 nM), providing a >1300-fold NTS2 selectivity. The (6-OH)Tic-containing analogue 9 also exhibited high NTS2 affinity (Ki = 1.7 nM), with low NTS1 affinity (Ki = 4.7 μM), resulting in an excellent NTS2 selectivity (>2700). In mice, hybrid 7 produced significant and prolonged antinociception (up to 8 h), as compared to the KGOP01 opioid parent compound.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Disease Models, Animal
- Drug Design
- Humans
- Male
- Mice
- Oligopeptides/chemistry
- Oligopeptides/metabolism
- Oligopeptides/therapeutic use
- Pain/drug therapy
- Pain/pathology
- Peptides/chemistry
- Peptides/metabolism
- Peptides/therapeutic use
- Protein Binding
- Receptors, Neurotensin/chemistry
- Receptors, Neurotensin/metabolism
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/metabolism
- Structure-Activity Relationship
Collapse
Affiliation(s)
- Simon Gonzalez
- Research
Group of Organic Chemistry, Departments of Chemistry and Bioengineering
Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium
| | - Maria Dumitrascuta
- Department
of Pharmaceutical Chemistry, Institute of Pharmacy and Center for
Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria
| | - Emilie Eiselt
- Department
of Pharmacology and Physiology, Faculty of Medicine and Health Sciences,
Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, J1H 5N4 Sherbrooke, Canada
| | - Stevany Louis
- Department
of Pharmaceutical Chemistry, Institute of Pharmacy and Center for
Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria
| | - Linda Kunze
- Department
of Pharmaceutical Chemistry, Institute of Pharmacy and Center for
Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria
| | - Annalisa Blasiol
- Department
of Pharmaceutical Chemistry, Institute of Pharmacy and Center for
Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria
| | - Mélanie Vivancos
- Department
of Pharmacology and Physiology, Faculty of Medicine and Health Sciences,
Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, J1H 5N4 Sherbrooke, Canada
| | - Santo Previti
- Research
Group of Organic Chemistry, Departments of Chemistry and Bioengineering
Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium
| | - Elke Dewolf
- Research
Group of Organic Chemistry, Departments of Chemistry and Bioengineering
Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium
| | - Charlotte Martin
- Research
Group of Organic Chemistry, Departments of Chemistry and Bioengineering
Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium
| | - Dirk Tourwé
- Research
Group of Organic Chemistry, Departments of Chemistry and Bioengineering
Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium
| | - Florine Cavelier
- Institut
des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, 34095 Montpellier, France
| | - Louis Gendron
- Department
of Pharmacology and Physiology, Faculty of Medicine and Health Sciences,
Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, J1H 5N4 Sherbrooke, Canada
| | - Philippe Sarret
- Department
of Pharmacology and Physiology, Faculty of Medicine and Health Sciences,
Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, J1H 5N4 Sherbrooke, Canada
| | - Mariana Spetea
- Department
of Pharmaceutical Chemistry, Institute of Pharmacy and Center for
Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria
| | - Steven Ballet
- Research
Group of Organic Chemistry, Departments of Chemistry and Bioengineering
Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium
| |
Collapse
|
5
|
Fanelli R, Chastel A, Previti S, Hindié E, Vimont D, Zanotti-Fregonara P, Fernandez P, Garrigue P, Lamare F, Schollhammer R, Balasse L, Guillet B, Rémond E, Morgat C, Cavelier F. Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging. Bioconjug Chem 2020; 31:2339-2349. [DOI: 10.1021/acs.bioconjchem.0c00419] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Roberto Fanelli
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| | - Adrien Chastel
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Santo Previti
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| | - Elif Hindié
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Delphine Vimont
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
| | | | - Philippe Fernandez
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Philippe Garrigue
- Aix-Marseille University, INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Marseille 13385, France
- Aix-Marseille University, Centre Européen de Recherche en Imagerie Médicale, Marseille 13005, France
| | - Frédéric Lamare
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Romain Schollhammer
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Laure Balasse
- Aix-Marseille University, INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Marseille 13385, France
| | - Benjamin Guillet
- Aix-Marseille University, INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Marseille 13385, France
- Aix-Marseille University, Centre Européen de Recherche en Imagerie Médicale, Marseille 13005, France
| | - Emmanuelle Rémond
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| | - Clément Morgat
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Florine Cavelier
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| |
Collapse
|
6
|
Tétreault P, Besserer-Offroy É, Brouillette RL, René A, Murza A, Fanelli R, Kirby K, Parent AJ, Dubuc I, Beaudet N, Côté J, Longpré JM, Martinez J, Cavelier F, Sarret P. Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog. Eur J Pharmacol 2020; 882:173174. [DOI: 10.1016/j.ejphar.2020.173174] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 04/28/2020] [Accepted: 05/04/2020] [Indexed: 12/14/2022]
|
7
|
Data set describing the in vitro biological activity of JMV2009, a novel silylated neurotensin(8-13) analog. Data Brief 2020; 31:105884. [PMID: 32637491 PMCID: PMC7327804 DOI: 10.1016/j.dib.2020.105884] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 06/05/2020] [Accepted: 06/12/2020] [Indexed: 12/12/2022] Open
Abstract
Neurotensin (NT) is a tridecapeptide displaying interesting antinociceptive properties through its action on its receptors, NTS1 and NTS2. Neurotensin-like compounds have been shown to exert better antinociceptive properties than morphine at equimolar doses. In this article, we characterized the molecular effects of a novel neurotensin (8-13) (NT(8-13)) analog containing an unnatural amino acid. This compound, named JMV2009, displays a Silaproline in position 10 in replacement of a proline in the native NT(8-13). We first examined the binding affinities of this novel NT(8-13) derivative at both NTS1 and NTS2 receptor sites by performing competitive displacement of iodinated NT on purified cell membranes. Then, we evaluated the ability of JMV2009 to activate NTS1-related G proteins as well as to promote the recruitment of β-arrestins 1 and 2 by using BRET-based cellular assays in live cells. We next assessed its ability to induce p42/p44 MAPK phosphorylation and NT receptors internalization using western blot and cell-surface ELISA, respectively. Finally, we determined the in vitro plasma stability of this NT derivative. This article is associated with the original article "Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog" published in European Journal of Pharmacology[1]. The reader is directed to the associated article for results interpretation, comments, and discussion.
Collapse
|
8
|
Ferkous H, Djellali S, Sahraoui R, Benguerba Y, Behloul H, Çukurovali A. Corrosion inhibition of mild steel by 2-(2-methoxybenzylidene) hydrazine-1-carbothioamide in hydrochloric acid solution: Experimental measurements and quantum chemical calculations. J Mol Liq 2020. [DOI: 10.1016/j.molliq.2020.112957] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
9
|
Eiselt E, Gonzalez S, Martin C, Chartier M, Betti C, Longpré JM, Cavelier F, Tourwé D, Gendron L, Ballet S, Sarret P. Neurotensin Analogues Containing Cyclic Surrogates of Tyrosine at Position 11 Improve NTS2 Selectivity Leading to Analgesia without Hypotension and Hypothermia. ACS Chem Neurosci 2019; 10:4535-4544. [PMID: 31589400 DOI: 10.1021/acschemneuro.9b00390] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Neurotensin (NT) exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2. This opioid-independent antinociception represents a potential alternative for pain management. While activation of NTS1 also induces a drop in blood pressure and body temperature, NTS2 appears to be an analgesic target free of these adverse effects. Here, we report modifications of NT at Tyr11 to increase selectivity toward NTS2, complemented by modifications at the N-terminus to impair proteolytic degradation of the biologically active NT(8-13) sequence. Replacement of Tyr11 by either 6-OH-Tic or 7-OH-Tic resulted in a significant loss of binding affinity to NTS1 and subsequent NTS2 selectivity. Incorporation of the unnatural amino acid β3hLys at position 8 increased the half-life to over 24 h in plasma. Simultaneous integration of both β3hLys8 and 6-OH-Tic11 into NT(8-13) produced a potent and NTS2-selective analogue with strong analgesic action after intrathecal delivery in the rat formalin-induced pain model with an ED50 of 1.4 nmol. Additionally, intravenous administration of this NT analogue did not produce persistent hypotension or hypothermia. These results demonstrate that NT analogues harboring unnatural amino acids at positions 8 and 11 can enhance crucial pharmacokinetic and pharmacodynamic features for NT(8-13) analogues, i.e., proteolytic stability, NTS2 selectivity, and improved analgesic/adverse effect ratio.
Collapse
Affiliation(s)
- Emilie Eiselt
- Département de pharmacologie et physiologie, Institut de pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec J1H 5H4, Canada
| | - Simon Gonzalez
- Research Group of Organic Chemistry, Departments of Bioengineering Sciences and Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, Brussels 1050, Belgium
| | - Charlotte Martin
- Research Group of Organic Chemistry, Departments of Bioengineering Sciences and Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, Brussels 1050, Belgium
| | - Magali Chartier
- Département de pharmacologie et physiologie, Institut de pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec J1H 5H4, Canada
| | - Cecilia Betti
- Research Group of Organic Chemistry, Departments of Bioengineering Sciences and Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, Brussels 1050, Belgium
| | - Jean-Michel Longpré
- Département de pharmacologie et physiologie, Institut de pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec J1H 5H4, Canada
| | - Florine Cavelier
- Institut des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France
| | - Dirk Tourwé
- Research Group of Organic Chemistry, Departments of Bioengineering Sciences and Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, Brussels 1050, Belgium
| | - Louis Gendron
- Département de pharmacologie et physiologie, Institut de pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec J1H 5H4, Canada
| | - Steven Ballet
- Research Group of Organic Chemistry, Departments of Bioengineering Sciences and Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, Brussels 1050, Belgium
| | - Philippe Sarret
- Département de pharmacologie et physiologie, Institut de pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec J1H 5H4, Canada
| |
Collapse
|
10
|
Kondratov IS, Logvinenko IG, Tolmachova NA, Morev RN, Kliachyna MA, Clausen F, Daniliuc CG, Haufe G. Synthesis and physical chemical properties of 2-amino-4-(trifluoromethoxy)butanoic acid - a CF 3O-containing analogue of natural lipophilic amino acids. Org Biomol Chem 2018; 15:672-679. [PMID: 27976770 DOI: 10.1039/c6ob02436j] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
2-Amino-2-(trifluoromethoxy)butanoic acid (O-trifluoromethyl homoserine) was synthesized as a racemate and in both enantiomeric forms. The measured pKa and log D values establish the compound as a promising analogue of natural aliphatic amino acids.
Collapse
Affiliation(s)
- Ivan S Kondratov
- Enamine Ltd, Chervonotkatska St 78, Kyiv, 02094, Ukraine. and Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine, Murmanska Str. 1, Kyiv, 02660, Ukraine
| | - Ivan G Logvinenko
- Enamine Ltd, Chervonotkatska St 78, Kyiv, 02094, Ukraine. and Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine, Murmanska Str. 1, Kyiv, 02660, Ukraine
| | - Nataliya A Tolmachova
- Enamine Ltd, Chervonotkatska St 78, Kyiv, 02094, Ukraine. and Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine, Murmanska Str. 1, Kyiv, 02660, Ukraine
| | - Roman N Morev
- Enamine Ltd, Chervonotkatska St 78, Kyiv, 02094, Ukraine.
| | | | - Florian Clausen
- Organisch-Chemisches Institut, Universität Münster, Corrensstraße 40, Münster 48149, Germany.
| | - Constantin G Daniliuc
- Organisch-Chemisches Institut, Universität Münster, Corrensstraße 40, Münster 48149, Germany.
| | - Günter Haufe
- Organisch-Chemisches Institut, Universität Münster, Corrensstraße 40, Münster 48149, Germany. and Cells-in-Motion Cluster of Excellence, Universität Münster, Waldeyerstraße 15, 48149 Münster, Germany
| |
Collapse
|
11
|
Fanelli R, Floquet N, Besserer-Offroy É, Delort B, Vivancos M, Longpré JM, Renault P, Martinez J, Sarret P, Cavelier F. Use of Molecular Modeling to Design Selective NTS2 Neurotensin Analogues. J Med Chem 2017; 60:3303-3313. [DOI: 10.1021/acs.jmedchem.6b01848] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Roberto Fanelli
- Institut
des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier cedex 5, France
| | - Nicolas Floquet
- Institut
des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier cedex 5, France
| | - Élie Besserer-Offroy
- Department
of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke,
Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Bartholomé Delort
- Institut
des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier cedex 5, France
| | - Mélanie Vivancos
- Department
of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke,
Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Jean-Michel Longpré
- Department
of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke,
Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Pedro Renault
- Institut
des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier cedex 5, France
- Centre
de Biochimie Structurale (CBS), UMR-5048, CNRS, Université de Montpellier, INSERM U1054, 29 rue de Navacelles, 34090 Montpellier, France
| | - Jean Martinez
- Institut
des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier cedex 5, France
| | - Philippe Sarret
- Department
of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke,
Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Florine Cavelier
- Institut
des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier cedex 5, France
| |
Collapse
|
12
|
Abstract
Unusual amino acids are fundamental building blocks of modern medicinal chemistry. The combination of readily functionalized amine and carboxyl groups attached to a chiral central core along with one or two potentially diverse side chains provides a unique three-dimensional structure with a high degree of functionality. This makes them invaluable as starting materials for syntheses of complex molecules, highly diverse elements for SAR campaigns, integral components of peptidomimetic drugs, and potential drugs on their own. This Perspective highlights the diversity of unnatural amino acid structures found in hit-to-lead and lead optimization campaigns and clinical stage and approved drugs, reflecting their increasingly important role in medicinal chemistry.
Collapse
Affiliation(s)
- Mark A T Blaskovich
- Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland Australia 4072
| |
Collapse
|
13
|
Rémond E, Martin C, Martinez J, Cavelier F. Silicon-Containing Amino Acids: Synthetic Aspects, Conformational Studies, and Applications to Bioactive Peptides. Chem Rev 2016; 116:11654-11684. [DOI: 10.1021/acs.chemrev.6b00122] [Citation(s) in RCA: 173] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Emmanuelle Rémond
- Institut
des Biomolécules
Max Mousseron, Unité Mixte de Recherche 5247 de Centre National
de la Recherche Scientifique, École Nationale Supérieure de Chimie de Montpellier, Université Montpellier, Place Eugène
Bataillon, 34095 Montpellier Cedex 5, France
| | - Charlotte Martin
- Institut
des Biomolécules
Max Mousseron, Unité Mixte de Recherche 5247 de Centre National
de la Recherche Scientifique, École Nationale Supérieure de Chimie de Montpellier, Université Montpellier, Place Eugène
Bataillon, 34095 Montpellier Cedex 5, France
| | - Jean Martinez
- Institut
des Biomolécules
Max Mousseron, Unité Mixte de Recherche 5247 de Centre National
de la Recherche Scientifique, École Nationale Supérieure de Chimie de Montpellier, Université Montpellier, Place Eugène
Bataillon, 34095 Montpellier Cedex 5, France
| | - Florine Cavelier
- Institut
des Biomolécules
Max Mousseron, Unité Mixte de Recherche 5247 de Centre National
de la Recherche Scientifique, École Nationale Supérieure de Chimie de Montpellier, Université Montpellier, Place Eugène
Bataillon, 34095 Montpellier Cedex 5, France
| |
Collapse
|